Loading...

Celyad

DB:1C0
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1C0
DB
€219M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The last earnings update was 19 days ago. More info.


Add to Portfolio Compare Print
1C0 Share Price and Events
7 Day Returns
-2.7%
DB:1C0
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-26%
DB:1C0
-7.4%
DE Biotechs
-5.6%
DE Market
1C0 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Celyad (1C0) -2.7% 0.9% -6.3% -26% -56.4% -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 1C0 underperformed the Biotechs industry which returned -7.4% over the past year.
  • 1C0 underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
1C0
Industry
5yr Volatility vs Market

Value

 Is Celyad undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Celyad. This is due to cash flow or dividend data being unavailable. The share price is €18.32.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Celyad's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Celyad's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1C0 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-3.36
ENXTBR:CYAD Share Price ** ENXTBR (2019-04-24) in EUR €18.32
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Celyad.

DB:1C0 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:CYAD Share Price ÷ EPS (both in EUR)

= 18.32 ÷ -3.36

-5.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celyad is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Celyad is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Celyad's expected growth come at a high price?
Raw Data
DB:1C0 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
2.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Celyad, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Celyad's assets?
Raw Data
DB:1C0 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €4.65
ENXTBR:CYAD Share Price * ENXTBR (2019-04-24) in EUR €18.32
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:1C0 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:CYAD Share Price ÷ Book Value per Share (both in EUR)

= 18.32 ÷ 4.65

3.94x

* Primary Listing of Celyad.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celyad is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Celyad's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Celyad has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Celyad expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
2.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Celyad expected to grow at an attractive rate?
  • Celyad's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Celyad's earnings growth is positive but not above the Germany market average.
  • Celyad's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1C0 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1C0 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 2.7%
DB:1C0 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 52.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1C0 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1C0 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 125 -27 5 2
2022-12-31 24 -36 -19 2
2021-12-31 73 -52 -61 4
2020-12-31 4 -43 -49 8
2019-12-31 4 -54 -39 6
DB:1C0 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -27 -37
2018-09-30 3 -49
2018-06-30 3 -44 -60
2018-03-31 3 -44 -58
2017-12-31 4 -44 -56
2017-09-30 9 -39
2017-06-30 12 -18 -21
2017-03-31 10 -22 -22
2016-12-31 10 -25 -24
2016-09-30 4 -31 -27
2016-06-30 0 -38 -31
2016-03-31 0 -32 -30

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Celyad's earnings are expected to grow by 2.7% yearly, however this is not considered high growth (20% yearly).
  • Celyad's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1C0 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Celyad Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1C0 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -5.69 -3.38 -8.00 2.00
2019-12-31 -3.93 -2.67 -6.00 3.00
DB:1C0 Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -3.36
2018-09-30 -4.62
2018-06-30 -6.01
2018-03-31 -5.94
2017-12-31 -5.86
2017-09-30 -4.07
2017-06-30 -2.24
2017-03-31 -2.39
2016-12-31 -2.53
2016-09-30 -2.89
2016-06-30 -3.24
2016-03-31 -3.33

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Celyad will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Celyad's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Celyad has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Celyad performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Celyad's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Celyad does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Celyad's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Celyad's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Celyad's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Celyad Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1C0 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.12 -37.43 10.39 23.58
2018-09-30 2.83 -48.93 10.46 23.24
2018-06-30 2.55 -60.44 10.52 22.90
2018-03-31 3.05 -58.42 9.92 22.90
2017-12-31 3.54 -56.40 9.31 22.91
2017-09-30 9.25 -38.75 9.28 23.14
2017-06-30 11.99 -21.10 9.25 23.38
2017-03-31 10.26 -22.35 9.50 25.53
2016-12-31 10.01 -23.61 9.74 27.68
2016-09-30 4.28 -27.15 9.04 27.17
2016-06-30 0.04 -30.70 8.34 26.67
2016-03-31 0.02 -29.91 7.79 24.72
2015-12-31 0.00 -29.11 7.23 22.77
2015-09-30 0.07 -27.26 6.93 21.82
2015-06-30 0.15 -25.41 6.62 20.88
2015-03-31 0.15 -20.93 5.82 18.37
2014-12-31 0.15 -16.45 5.02 15.87
2014-09-30 0.07 -15.45 5.06 15.18
2014-06-30 -14.44 5.10 14.49
2014-03-31 -14.95 4.51 11.77
2013-12-31 -14.49 3.97 9.05
2013-09-30 0.03 -12.77 2.38 2.28
2013-06-30 0.05 -13.20 1.77 2.41
2013-03-31 0.05 -11.90 1.85 2.69
2012-12-31 0.05 -13.52 1.88 3.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Celyad has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Celyad has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Celyad improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Celyad's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Celyad has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Celyad's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Celyad's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Celyad is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Celyad's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Celyad's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 31.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Celyad Company Filings, last reported 3 months ago.

DB:1C0 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 55.59 1.65 49.74
2018-09-30 55.59 1.65 49.74
2018-06-30 72.68 1.30 63.23
2018-03-31 72.68 1.30 63.23
2017-12-31 47.54 1.44 33.91
2017-09-30 47.54 1.44 33.91
2017-06-30 77.25 1.20 68.84
2017-03-31 77.25 1.20 68.84
2016-12-31 90.89 1.48 82.59
2016-09-30 90.89 1.48 82.59
2016-06-30 96.63 1.74 86.03
2016-03-31 96.63 1.74 86.03
2015-12-31 111.47 0.68 107.51
2015-09-30 111.47 0.68 107.51
2015-06-30 124.89 0.50 123.79
2015-03-31 124.89 0.50 123.79
2014-12-31 26.68 0.41 30.30
2014-09-30 26.68 0.41 30.30
2014-06-30 35.68 0.32 40.07
2014-03-31 35.68 0.32 40.07
2013-12-31 16.90 0.11 22.06
2013-09-30 16.90 0.11 22.06
2013-06-30 -1.12 0.17 3.94
2013-03-31 -4.44 0.22 0.11
2012-12-31 -2.26 0.27 1.65
  • Celyad's level of debt (3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.6% vs 3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Celyad has sufficient cash runway for 1.7 years based on current free cash flow.
  • Celyad has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 7.4% each year.
X
Financial health checks
We assess Celyad's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Celyad has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Celyad's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Celyad dividends. Estimated to be 0% next year.
If you bought €2,000 of Celyad shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Celyad's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Celyad's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1C0 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1C0 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Celyad has not reported any payouts.
  • Unable to verify if Celyad's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Celyad's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Celyad has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Celyad's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Celyad's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Celyad afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Celyad has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Celyad's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Filippo Petti
AGE 46
TENURE AS CEO 0 years
CEO Bio

Mr. Filippo Joseph Petti has been the Chief Executive Officer and Chief Financial Officer of Celyad SA since April 1, 2019. Mr. Petti served as the Chief Financial Officer at Celyad SA since September 2018 until April 1, 2019. Mr. Petti served as Chief Financial Officer and Investor Relations at Celyad SA since September 03, 2018 until September 2018. He currently serves as vice president of healthcare investment banking at Wells Fargo Securities. Before joining Wells Fargo Securities, he was vice president of healthcare investment banking at William Blair & Company. Prior to his roles in investment banking, Mr. Petti worked in equity research both at William Blair & Company and Wedbush Securities. He began his career as a research scientist at OSI Pharmaceuticals, Inc. before transitioning to corporate development with the company. Mr. Petti holds a Master of Business Administration from Cornell University, a Master of Science from St. John’s University and a Bachelor of Science from Syracuse University.

CEO Compensation
  • Insufficient data for Filippo to compare compensation growth.
  • Insufficient data for Filippo to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Celyad management team in years:

2.4
Average Tenure
48
Average Age
  • The tenure for the Celyad management team is about average.
Management Team

Michel Lussier

TITLE
Co-Founder & Chairman
COMPENSATION
€86K
AGE
62

Filippo Petti

TITLE
CEO & CFO
AGE
46

Jean-Pierre Latere

TITLE
Chief Operating Officer
AGE
43
TENURE
2.3 yrs

Nicolas Van Hoecke

TITLE
Director of Investor Relations & Communications
TENURE
0.6 yrs

Philippe Dechamps

TITLE
Chief Legal Officer
AGE
48
TENURE
2.6 yrs

Philippe Nobels

TITLE
Global Head of Human Resources
AGE
52
TENURE
2.5 yrs
Board of Directors Tenure

Average tenure and age of the Celyad board of directors in years:

7.5
Average Tenure
58.5
Average Age
  • The tenure for the Celyad board of directors is about average.
Board of Directors

Michel Lussier

TITLE
Co-Founder & Chairman
COMPENSATION
€86K
AGE
62
TENURE
12.3 yrs

Christian Homsy

TITLE
Director
COMPENSATION
€477K
AGE
60
TENURE
12.3 yrs

Serge Goblet

TITLE
Non-Executive Director
COMPENSATION
€36K
AGE
60
TENURE
11.3 yrs

Chris Buyse

TITLE
Independent Director
COMPENSATION
€71K
AGE
54
TENURE
11.3 yrs

Rudy DeKeyser

TITLE
Independent Director
COMPENSATION
€81K
AGE
56
TENURE
12.3 yrs

Debasish Roychowdhury

TITLE
Independent Director
COMPENSATION
€62K
AGE
57
TENURE
3.7 yrs

Hinrich Abken

TITLE
Member of Scientific Advisory Board
TENURE
3 yrs

Scott Antonia

TITLE
Member of Scientific Advisory Board
TENURE
3 yrs

Marco Davila

TITLE
Member of Scientific Advisory Board
TENURE
3 yrs

Marc Ernstoff

TITLE
Member of Scientific Advisory Board
TENURE
3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Celyad's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Celyad has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company’s lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.

Details
Name: Celyad SA
1C0
Exchange: DB
Founded: 2004
€218,783,742
11,942,344
Website: http://www.celyad.com
Address: Celyad SA
Axis Business Park,
Rue Edouard Belin 2,
Mont-Saint-Guibert,
Walloon Brabant, 1435,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR CYAD Ordinary Shares Euronext Brussels BE EUR 04. Jul 2013
OTCPK CLYY.F Ordinary Shares Pink Sheets LLC US USD 04. Jul 2013
DB 1C0 Ordinary Shares Deutsche Boerse AG DE EUR 04. Jul 2013
LSE 0QFK Ordinary Shares London Stock Exchange GB EUR 04. Jul 2013
BATS-CHIXE CYADB Ordinary Shares BATS 'Chi-X Europe' GB EUR 04. Jul 2013
NasdaqGM CYAD ADR Nasdaq Global Market US USD 22. Jun 2015
Number of employees
Current staff
Staff numbers
94
Celyad employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:29
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/21
Last earnings filing: 2019/04/05
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.